Macrogenics Inc (MGNX)
3.57
-0.24
(-6.30%)
USD |
NASDAQ |
Nov 15, 16:00
3.57
0.00 (0.00%)
Pre-Market: 20:00
Macrogenics Research and Development Expense (TTM): 185.66M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 185.66M |
| June 30, 2024 | 175.24M |
| March 31, 2024 | 166.74M |
| December 31, 2023 | 166.58M |
| September 30, 2023 | 164.89M |
| June 30, 2023 | 182.95M |
| March 31, 2023 | 191.46M |
| December 31, 2022 | 207.03M |
| September 30, 2022 | 217.23M |
| June 30, 2022 | 218.86M |
| March 31, 2022 | 222.89M |
| December 31, 2021 | 214.58M |
| September 30, 2021 | 201.02M |
| June 30, 2021 | 195.86M |
| March 31, 2021 | 197.43M |
| December 31, 2020 | 193.20M |
| September 30, 2020 | 202.86M |
| June 30, 2020 | 203.05M |
| March 31, 2020 | 197.14M |
| December 31, 2019 | 195.31M |
| September 30, 2019 | 190.28M |
| June 30, 2019 | 191.64M |
| March 31, 2019 | 192.22M |
| Date | Value |
|---|---|
| December 31, 2018 | 190.83M |
| September 30, 2018 | 182.89M |
| June 30, 2018 | 177.65M |
| March 31, 2018 | 160.10M |
| December 31, 2017 | 147.23M |
| September 30, 2017 | 139.36M |
| June 30, 2017 | 128.67M |
| March 31, 2017 | 127.55M |
| December 31, 2016 | 122.09M |
| September 30, 2016 | 121.03M |
| June 30, 2016 | 114.83M |
| March 31, 2016 | 104.15M |
| December 31, 2015 | 98.27M |
| September 30, 2015 | 87.88M |
| June 30, 2015 | 82.41M |
| March 31, 2015 | 77.08M |
| December 31, 2014 | 70.19M |
| September 30, 2014 | 64.88M |
| June 30, 2014 | 57.34M |
| March 31, 2014 | 51.05M |
| December 31, 2013 | 46.58M |
| September 30, 2013 | 40.74M |
| June 30, 2013 | 41.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
164.89M
Minimum
Sep 2023
222.89M
Maximum
Mar 2022
195.00M
Average
196.50M
Median
Research and Development Expense (TTM) Benchmarks
| KORU Medical Systems Inc | 5.191M |
| Apellis Pharmaceuticals Inc | 320.50M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |